about
Patient-Reported Outcomes in Glomerular Disease.Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study designHypertension and health outcomes in the PICU.A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular diseaseTherapeutic approach to FSGS in children.Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.Complement Activation in Patients with Focal Segmental Glomerulosclerosis.Development of a Pediatric Adverse Events TerminologyPublic participation in, and awareness about, medical research opportunities in the era of clinical and translational research.Neurocognitive, Social-Behavioral, and Adaptive Functioning in Preschool Children with Mild to Moderate Kidney DiseaseInpatient health care utilization by children and adolescents with systemic lupus erythematosus and kidney involvementRenal manifestations of systemic illness in children.Patient Engagement in Neurological Clinical Trials Design: A Conference Summary.Implications of different fluid overload definitions in pediatric stem cell transplant patients requiring continuous renal replacement therapy.Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO.Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO.Treatment outcome of late steroid-resistant nephrotic syndrome: a study by the Midwest Pediatric Nephrology Consortium.Treatment of FSGS in Children.A unified framework for evaluating the risk of re-identification of text de-identification tools.Matching the Genotype in Resolution: Innovative Ways of Phenotype Capture.Development of Focal Segmental Glomerulosclerosis Patient-Reported Outcome Measures: Symptom Diary and Symptom Impact Questionnaire.Provider perspectives on treatment decision-making in nephrotic syndrome.The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseasesLearning to live with nephrotic syndrome: experiences of adult patients and parents of children with nephrotic syndrome.Management patterns of childhood-onset nephrotic syndrome.Regarding Maas's editorial letter on serum suPAR levels.The differential effect of race among pediatric kidney transplant recipients with focal segmental glomerulosclerosis.Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET).Differential risk of remission and ESRD in childhood FSGS.Inpatient health care utilization in the United States among children, adolescents, and young adults with nephrotic syndrome.An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis.Prevalence of sleep disturbances in children and adolescents with chronic kidney disease.Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease.A clinical tool to measure the components of health-care transition from pediatric care to adult care: the UNC TR(x)ANSITION scale.Memory and executive functions in pediatric chronic kidney disease.A measure of success in kidney transplantations.Improving the evidence for the management of childhood nephrotic syndromeA possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS)The authors reply
P50
Q30249861-B045F530-574C-46E3-A902-89921846A7DBQ33527568-DDA4D9C5-9E7C-4890-8442-2A565172704FQ33817568-76841AB7-1532-49D0-B225-1EF85522A88AQ33980420-3793370D-0D5B-418D-BEB3-DE2829D69448Q35132279-E765DF28-A93C-4F59-9517-70F8C831E6CCQ35614311-B86EF9C3-B1D0-4B8D-B541-194ECA993DE2Q35704498-B237E1F9-BDFA-4839-B978-71CA19C8025EQ35763276-5864E135-8512-4CC1-A3EB-AFE8EE9FE9DAQ36234133-BEE3CEE8-9887-42E1-ABBF-DE4EC1E4EA81Q36549414-0C551607-7C19-400B-8971-01F7A7A4D7F4Q36757796-72D4E804-D642-4CC0-8AF5-216ED0B4FE13Q37256607-FF11EDD0-7E05-4F5B-9DBD-2BC4FBC5F71CQ37555055-EBAC0BF5-1692-48EB-B7A4-B78AD846D5DBQ37700887-4490E6EF-1475-419D-80D2-B22087441090Q37983429-06000F55-9302-444C-A8E8-088217348065Q38050959-FB1BD8CF-F193-4F13-9D5A-923E3A448698Q38050961-010FDB27-529C-43C6-A8CB-CBA3EE1C518EQ38103188-69FB32A4-5F34-40D8-9488-2ED012D441A6Q38193933-DF792EEC-AD2C-4C53-B40B-EAC74FFF8614Q38386046-627976AD-548B-469D-A2B7-0D77631DD985Q38555419-67B7179C-5002-43A1-8D67-B89A0468FD16Q38664915-BEB3714E-3495-4936-B8AF-28C952B70B50Q38733012-68F9F3CA-F0EE-44E3-843F-D63034212892Q38830976-BCA6F298-10AF-48CA-95ED-A734FCE29D2CQ38846072-F9B5B7ED-DC8B-49A6-A85D-51B7B0EEF3C6Q39956110-49FA80DF-AAD7-49D5-B415-F2234130FE1DQ42406462-40B34249-38AF-47EE-BDE5-C0B69FA95E4FQ42628239-33EA40B1-2272-4EA7-978B-1B28B2326F74Q46399341-CCEDD0FB-F53F-43A2-8741-ED25679B99CEQ46893726-D5491C61-75AC-4E36-89B8-381964BAB55CQ46915770-90709C92-A4E3-45BA-B757-7A886B22568DQ47372786-7A4BD169-1C6D-43AB-82E4-28CF5A86730BQ48280662-E4CE2A6F-1667-478F-9D27-AFB363A00B62Q50867897-A8A2EE6E-D54F-46D5-B865-D250C5379A71Q50945135-43E14481-04D4-4EAA-99AC-7DF3BC4DB5B7Q51979632-6299957E-3016-49F5-A645-1309AF4CA1EDQ53349600-0E0967FE-BE5A-4322-B67E-5062BBFD83BAQ59459299-D3EFC5DA-C15F-494D-8A74-870741AC90B0Q59459357-E4DF0358-8A6F-452E-9855-00F82ED2DE40Q59459392-06BC5474-6B8D-4438-9569-91CDF49B7842
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Debbie S Gipson
@ast
Debbie S Gipson
@en
Debbie S Gipson
@es
Debbie S Gipson
@nl
Debbie S Gipson
@sl
type
label
Debbie S Gipson
@ast
Debbie S Gipson
@en
Debbie S Gipson
@es
Debbie S Gipson
@nl
Debbie S Gipson
@sl
prefLabel
Debbie S Gipson
@ast
Debbie S Gipson
@en
Debbie S Gipson
@es
Debbie S Gipson
@nl
Debbie S Gipson
@sl
P106
P21
P31
P496
0000-0003-4473-9045